-
An initiative to cut down on the use of the emergency department (ED) for non-emergent care by educating patients on more appropriate levels of care resulted in an 11.5% decline in ED use in three years by members covered by Blue Cross and Blue Shield of Florida, with headquarters in Jacksonville.
-
Managing the care of Medicaid members and ensuring that they obtain the services they need is always a challenge, case managers report.
-
On Aug. 10, 2011, the Food and Drug Administration (FDA) approved Complera, a fixed dose combination (FDC) drug product containing emtricitabine/rilpivirine/tenofovir DF (FTC/RPV/TDF) for the treatment of HIV. The recommended dose of Complera is one tablet, containing 200mg/25mg/300mg of FTC/RPV/TDF, once daily, taken orally with a meal.
-
The Joint Commission recently posted the following answer to a frequently asked question on screening for methicillin-resistant Staphylococcus aureus (MRSA).
-
The elements of performance for the CAUTI prevention safety goal are as follows:
-
The Joint Commission's new National Patient Safety Goal (NPSG) on preventing indwelling catheter-associated urinary tract infections which emphasizes prompt removal of unnecessary devices and surveillance for CAUTIs is effective January 1, 2012 for hospitals.
-
Field test results of an integrated microfluidic-based diagnostic device indicate that the potential
-
-
African-American girls from low-income neighborhoods who have had childhood violence exposure are significantly more likely to engage in high-risk sexual activities, researchers found.
-
New research suggests that roughly half of HIV patients might have some neurocognitive impairment, although most of this might be asymptomatic or mild.